Why is IQV stock up sharply today?

IQV surged +9.58% to $176.03 (per live market data) following strong Q4 2025 results and FY2026 guidance that exceeded the prior consensus of ~$11.50, with AI-driven analytics growth as the key narrative catalyst.

How does IQVIA's guidance affect the broader healthcare sector?

IQVIA's strong R&D bookings signal healthy biopharma pipeline spending, providing a mild positive read-through for peers in contract research and for diversified healthcare names like Johnson & Johnson.

Is IQVIA's FY2026 EPS guidance above or below Wall Street consensus?

The confirmed range of $12.55–$12.85 sits slightly below the FactSet consensus of $12.93, per Marketscreener, making any upward revision in Q1 2026 results the key near-term catalyst.

What is driving IQVIA's 2026 revenue growth outlook?

FX tailwinds (+100bps), acquisition contributions (+150bps), AI-integrated analytics services (+9.8% TAS YoY), and resilient biopharma R&D spending are the primary drivers cited in IQVIA's guidance framework.

Quick Links

IQVIA FY2026 Guidance Confirmed: $12.55–$12.85 EPS and $17.15B–$17.35B Revenue Signal Steady R&D-Driven Growth

Published: 2026-05-05 21:20:25 UTC

View IQV Page View Market Outlook

Data Snapshot

Price

$176.03

24h Low

$156.98

24h High

$176.92

24h Change

+9.58%

24h Change (%)

+9.58%

IQV Current Price

$176.03

Q4 2025 R&D Bookings

$2.7B (1.18x book-to-bill)

FY2025 Adj. EPS Actual

$11.92

FY2026 Revenue Guidance

$17.150B–$17.350B

FY2026 Adj. EPS Guidance

$12.55–$12.85

Key Takeaways

•FY2026 EPS guidance of $12.55–$12.85 represents ~5–8% growth over FY2025's $11.92, driven by AI integration and strong R&D bookings.
•IQV is up +9.58% to $176.03 on the day (live data), with intraday range $156.98–$176.92 reflecting a sharp post-earnings re-rating.
•Q4 2025 R&D bookings of $2.7B and a 1.18x book-to-bill ratio signal durable revenue visibility into 2026.
•Q1 2026 results released today (May 5) — any upward EPS revision above $12.85 would be the key incremental catalyst.
•Healthcare analytics peers and biopharma proxies like JNJ see modest positive read-through from IQVIA's R&D pipeline strength.

IQVIA Holdings (IQV) has issued its FY2026 full-year guidance following a strong Q4 2025 performance, confirming adjusted EPS of $12.55–$12.85 and revenue of $17.150B–$17.350B, according to IQVIA's of

Event Analysis

IQVIA Holdings (IQV) has issued its FY2026 full-year guidance following a strong Q4 2025 performance, confirming adjusted EPS of $12.55–$12.85 and revenue of $17.150B–$17.350B, according to IQVIA's official investor relations release. Note: the signal's claim of a raised EPS range to $12.65–$12.95 is unverified — all available sources confirm the original guidance range. The confirmed figures still represent approximately 5–8% EPS growth over FY2025's $11.92, supported by Q4 beats (revenue $4.364B, Adj. EPS $3.42) and R&D bookings of $2.7B with a healthy 1.18x book-to-bill ratio.

What makes this guidance cycle distinctive is IQVIA's deliberate pivot toward AI-integrated clinical and analytics services. As reported by AInvest, the AI push is directly credited with boosting the EPS outlook, with Technology & Analytics Solutions (TAS) revenue rising +9.8% year-over-year. Free cash flow reached $2.051B (99% of Adjusted Net Income), reinforcing balance sheet discipline. Acquisition and FX tailwinds are baked in, contributing an estimated +150bps and +100bps to revenue guidance respectively.

The broader context matters: IQVIA operates at the intersection of biopharma R&D spending and data analytics — a segment that has proven resilient even as broader healthcare faces margin pressure. With IQVIA's IQVIA Institute projecting sustained global R&D investment growth into 2026, the company is structurally well-positioned. This earnings cycle fits squarely within the diversified sector earnings beat wave theme, where services-oriented companies with recurring revenue are outperforming.

Q1 2026 results were scheduled for release today (May 5, 2026) per Businesswire — any upward revision to the EPS range would be the real catalyst to watch, as the current guidance sits slightly below the FactSet consensus estimate of $12.93, per Marketscreener.

What This Means for Traders

IQV is trading at $176.03 (up +9.58% on the day, per live data), with an intraday range of $156.98–$176.92 — the gap from the low reflects a sharp post-earnings re-rating already underway. For traders following the 2026 Stocks Market Outlook, this move confirms that healthcare services names with AI-linked narratives are attracting institutional rotation. The stock's single-day range suggests volatility remains elevated; momentum traders should watch whether IQV can hold above the $176 level as a new support zone.

Sector spillover is modest but real. Peers in contract research and healthcare analytics — and broader indices like the S&P 500 and NASDAQ 100 — may see mild sympathy lifts given the healthy R&D bookings signal. Johnson & Johnson and UnitedHealth Group benefit indirectly from a positive read-through on biopharma R&D pipeline activity. Traders looking for a structured framework can reference our guide on trading earnings beats for entry/exit frameworks around post-guidance consolidation setups.

Trade IQVIA Holdings, Inc. on CoinUnited.io

Trade IQV with up to 1000xx leverage → | Create Free Account

Frequently Asked Questions

IQVIA confirmed FY2026 adjusted EPS guidance of $12.55–$12.85, representing approximately 5–8% growth over FY2025's $11.92, according to IQVIA's investor relations release.